By Memorandum Opinion entered by The Honorable Sue L. Robinson in Amgen Inc. v. Sanofi, et al., Civil Action No. 14-317-SLR (D.Del., October 20, 2015), the Court rendered its Markman Opinion construing six (6) disputed terms in U.S. Patent Nos. 8,829,165("the '165 patent"), 8,859,741 ("the '741 patent"), and 8,871,914 ("the '914 patent").
A copy of the Memorandum Opinion is attached.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.